Lamivudine Teva Pharma B.V. (Lamivudine)

Lamivudine is taken up by cells and converted to its active triphosphate form. This analogue competes with natural nucleotides for incorporation into viral DNA by HIV reverse transcriptase and hepatitis B polymerase. Once incorporated, it terminates the DNA chain, halting viral replication and limiting disease spread.

The specific dose of lamivudine is determined by the prescribing healthcare professional based on the patient’s age, weight, renal function, and the condition being treated. Dosage regimens may differ for HIV versus hepatitis B, and adjustments are made according to clinical response and laboratory monitoring.

Lamivudine’s pregnancy category is not definitively established. It may be used during pregnancy only if the potential benefits outweigh the risks, and this decision should be made by a qualified obstetrician. Information on excretion in breast milk is limited; breastfeeding mothers should consult their physician to assess safety.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other antiretrovirals for a synergistic effect. Compared with older NRTIs, lamivudine generally has a more favorable safety profile and lower mitochondrial toxicity, but resistance can develop if used as monotherapy, making combination regimens preferred.

Lamivudine tablets should be stored at ambient temperature, below 25 °C, in their original container. Protect them from moisture, excessive heat and direct sunlight. Do not store in bathrooms or near kitchen appliances that generate steam, as humidity can affect tablet integrity.

Lamivudine is administered orally, usually as a tablet taken with or without food. The exact timing and frequency are prescribed by the treating physician, who will also advise whether the medication should be taken once daily or divided into multiple doses based on the therapeutic regimen.

Serious risks, though uncommon, include lactic acidosis, severe hepatotoxicity, pancreatitis, hypersensitivity reactions such as Stevens‑Johnson syndrome, and significant anemia. Patients should be monitored regularly for signs of metabolic disturbances, liver dysfunction, pancreatic pain, skin eruptions, or unexplained fatigue.

Lamivudine is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Individuals with severe renal impairment may require dose adjustment, and those with active, uncontrolled liver disease should be evaluated carefully before initiation. Pregnant or breastfeeding women should discuss potential risks with their healthcare provider.